PharmaCyte Biotech Statistics Share Statistics PharmaCyte Biotech has 6.86M
shares outstanding. The number of shares has increased by -10.62%
in one year.
Shares Outstanding 6.86M Shares Change (YoY) -10.62% Shares Change (QoQ) 0% Owned by Institutions (%) 8.16% Shares Floating 6.14M Failed to Deliver (FTD) Shares 200 FTD / Avg. Volume 1.13%
Short Selling Information The latest short interest is 10.43K, so 0.15% of the outstanding
shares have been sold short.
Short Interest 10.43K Short % of Shares Out 0.15% Short % of Float 0.17% Short Ratio (days to cover) 1
Valuation Ratios The PE ratio is 60.86 and the forward
PE ratio is null.
PharmaCyte Biotech's PEG ratio is
0.08.
PE Ratio 60.86 Forward PE n/a PS Ratio 0 Forward PS n/a PB Ratio 0.51 P/FCF Ratio -9.44 PEG Ratio 0.08
Financial Ratio History Enterprise Valuation PharmaCyte Biotech has an Enterprise Value (EV) of -29.87M.
EV / Sales 0 EV / EBITDA 0 EV / EBIT 13.88 EV / FCF 13.88
Financial Position The company has a current ratio of 6.8,
with a Debt / Equity ratio of 0.
Current Ratio 6.8 Quick Ratio 6.8 Debt / Equity 0 Debt / EBITDA n/a Debt / FCF n/a Interest Coverage 0
Financial Efficiency Return on Equity is 0.84% and Return on Invested Capital is -16.23%.
Return on Equity 0.84% Return on Assets 0.56% Return on Invested Capital -16.23% Revenue Per Employee n/a Profits Per Employee $166.88K Employee Count 2 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by -52.43% in the
last 52 weeks. The beta is -0.29, so PharmaCyte Biotech's
price volatility has been lower than the market average.
Beta -0.29 52-Week Price Change -52.43% 50-Day Moving Average 1.04 200-Day Moving Average 1.41 Relative Strength Index (RSI) 25.31 Average Volume (20 Days) 17,743
Income Statement
Revenue n/a Gross Profit n/a Operating Income -8.52M Net Income 333.76K EBITDA n/a EBIT -6.52M Earnings Per Share (EPS) -1.8
Full Income Statement Balance Sheet The company has 50.18M in cash and 0 in
debt, giving a net cash position of 50.18M.
Cash & Cash Equivalents 50.18M Total Debt n/a Net Cash n/a Retained Earnings -115.63M Total Assets 43.83M Working Capital 15.77M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -2.15M
and capital expenditures 0, giving a free cash flow of -2.15M.
Operating Cash Flow -2.15M Capital Expenditures n/a Free Cash Flow -2.15M FCF Per Share -0.22
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields PMCB does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield 1.64% FCF Yield -10.59%
Dividend Details Analyst Forecast Currently there are no analyst rating for PMCB.
Price Target n/a Price Target Difference n/a Analyst Consensus n/a Analyst Count n/a
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number 1.8 Graham Upside 104.55%
Stock Splits The last stock split was on Jul 12, 2021. It was a
backward
split with a ratio of 1:1550.
Last Split Date Jul 12, 2021 Split Type backward Split Ratio 1:1550
Scores Altman Z-Score -2.39 Piotroski F-Score 4
